LAVA Therapeutics Files 8-K: Regulatory, Other Events
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 8-K |
| Filed Date | Aug 14, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-disclosure, other-events, financials
TL;DR
LAVA Therapeutics filed an 8-K on Aug 13, 2025, covering Reg FD, other events, and financials.
AI Summary
LAVA Therapeutics N.V. filed an 8-K on August 14, 2025, reporting events as of August 13, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in The Netherlands and its principal executive offices are located in Utrecht.
Why It Matters
This 8-K filing provides updates on the company's regulatory disclosures and other significant events, which could impact investor understanding of its current operational status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting standard disclosures and does not appear to contain significant negative or positive news.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- August 13, 2025 (date) — Earliest event reported date
- August 14, 2025 (date) — Filing date
- The Netherlands (location) — Jurisdiction of incorporation and principal executive offices location
- Utrecht (location) — City of principal executive offices
FAQ
What specific events are disclosed under 'Regulation FD Disclosure'?
The filing indicates 'Regulation FD Disclosure' as an item, but the specific details of the disclosure are not provided in the excerpt.
What kind of 'Other Events' are reported by LAVA Therapeutics?
The filing lists 'Other Events' as a category, but the nature of these events is not detailed in the provided text.
Does the 8-K filing include any financial statements?
Yes, the filing explicitly mentions 'Financial Statements and Exhibits' as an item being reported.
When was LAVA Therapeutics N.V. incorporated?
The filing states the company's jurisdiction of incorporation is 'The Netherlands'.
What is the principal executive office address for LAVA Therapeutics N.V.?
The principal executive offices are located at Yalelaan 62, Utrecht, The Netherlands, 3584 CM.
Filing Stats: 1,001 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2025-08-14 16:27:29
Filing Documents
- tm2523552d1_8k.htm (8-K) — 29KB
- tm2523552d1_ex99-1.htm (EX-99.1) — 88KB
- tm2523552d1_ex99-1img01.jpg (GRAPHIC) — 6KB
- 0001104659-25-078654.txt ( ) — 302KB
- lvtx-20250813.xsd (EX-101.SCH) — 3KB
- lvtx-20250813_lab.xml (EX-101.LAB) — 33KB
- lvtx-20250813_pre.xml (EX-101.PRE) — 22KB
- tm2523552d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 13, 2025, LAVA Therapeutics N.V. (the "Company") issued a press release entitled "LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update," a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Other Information
Item 8.01 Other Information. Passive Foreign Investment Company Status The Company is updating its prior disclosures to reflect that it believes that it may have been classified as a passive foreign investment company ("PFIC") for its taxable year ended December 31, 2024 and may be classified as a PFIC in the current taxable year ending December 31, 2025. Because PFIC status depends upon the composition of the Company's income and assets and the market value of the Company's assets (including, among others, goodwill and less than 25% owned equity investments) from time to time, there can be no assurance that the Company will not be deemed a PFIC for the current taxable year or in the future. Please see the risk factor in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on March 28, 2025, under the heading, " We may be classified as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. investors in our common shares " as well as the section titled " Material U.S. Federal Income Tax Considerations for U.S. Holders—Passive foreign investment company " in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on March 20, 2024 for more information about the implications of PFIC classification. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Cautionary Note Regarding Forward-Looking Statements This Current Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "estimate," "plan," and similar expressions (as well as other words or expressions referencing futu
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LAVA Therapeutics, N.V. Dated: August 14, 2025 By: /s/ Fred Powell Name: Fred Powell Title: Chief Financial Officer